2022 World Conference on Lung Cancer (ePosters)-EP08.01-073. AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC

EP08.01-073. AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC

Back to course

Pdf Summary

A phase 1b study evaluated the combination of ociperlimab and tislelizumab in patients with advanced non-small cell lung cancer (NSCLC). The study showed promising antitumor activity, with an unconfirmed objective response rate (ORR) of 53.8%. Patients with higher PD-L1 expression had higher ORRs compared to patients with lower PD-L1 expression. The median duration of response was not evaluable, and median progression-free survival was 5.4 months. Safety analysis showed that the treatment was well-tolerated, with mild to moderate adverse events. The most common adverse events were pruritus, pyrexia, and decreased appetite. Serious adverse events occurred in 10% of patients, but there were no treatment-related deaths. The study was conducted by multiple institutions and research organizations across different countries. The authors disclose financial interests and affiliations with pharmaceutical companies. In conclusion, ociperlimab and tislelizumab showed promising efficacy in patients with advanced NSCLC, especially in those with higher PD-L1 expression. The treatment had an acceptable safety profile. Further research is needed to evaluate the long-term outcomes and potential benefits of this combination therapy in NSCLC patients.

Asset Subtitle

Rajiv Kumar

Meta Tag

Speaker Rajiv Kumar

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

phase 1b study

ociperlimab

tislelizumab

advanced non-small cell lung cancer

NSCLC

antitumor activity

objective response rate

PD-L1 expression

progression-free survival

safety analysis